RxDoctor Payments Data

Bruce Kava, MD

Urology · Miami, FLNPI 1265461826

Payments from drug & device makers

$50,580in general payments, 2019–2025

Across 278 payments — averaging $181.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merit Medical Systems Inc$15K
  • Endo USA, Inc.$14K
  • Coloplast$5K
  • Endo Pharmaceuticals Inc.$5K
  • Boehringer Ingelheim$5K
  • Boston Scientific$2K
  • plus $5K from 19 others

What the payments were for

  • Consulting fees$24,26555%
  • Speaking & faculty fees$4,57810%
  • Travel & lodging$3,9929%
  • Food & beverage$11,16025%
  • Education$1800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,580 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$328,969
Medicare patients
854
Services billed
3,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiaflexCollagenase Clostridium Hist.24$307,436
MyrbetriqMirabegron183$121,594
GemtesaVibegron83$68,006
Solifenacin Succinate165$8,681
Alfuzosin Hcl ErAlfuzosin Hcl370$7,759
Testosterone69$5,731
Tamsulosin Hcl357$5,692
Testosterone Cypionate160$4,756
Silodosin29$4,497
Methenamine Hippurate47$3,195
Finasteride126$1,778
Tadalafil19$1,322
Tolterodine Tartrate ErTolterodine Tartrate11$1,251
Oxybutynin Chloride ErOxybutynin Chloride38$951
Cabergoline17$859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Endo Pharmaceuticals Inc.Xiaflex$4,720$307,43624 claims
Astellas Pharma US IncMyrbetriq$222$121,594183 claims
Sumitomo Pharma America, Inc.Gemtesa$207$68,00683 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 urology providers in Florida.

Other urology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →